Irritable Bowel Syndrome News and Research

Latest Irritable Bowel Syndrome News and Research

Lexicon receives FDA Orphan Drug designation for telotristat etiprate to treat carcinoid syndrome

Lexicon Pharmaceuticals, Inc., announced today that the U.S. Food and Drug Administration (FDA) has granted its request for Orphan Drug designation for telotristat etiprate (LX1032) for the treatment of carcinoid syndrome.

21 Mar 2012

SK Biopharmaceuticals initiates YKP10811 phase 2 trial in chronic constipation

SK Biopharmaceuticals, a South Korean pharmaceutical company, announced today that the first patient was dosed in a phase 2 clinical trial in the US for patients suffering with chronic constipation using their new chemical entity YKP10811.

17 Mar 2012

Ovarian cancer – push for greater awareness

Women are being warned about ovarian cancer – mostly a silent killer, since many do not know what symptoms to look out for. Each year in the UK around 6,700 women are diagnosed with the disease and more than 4,000 women lose their lives.

12 Mar 2012

SK Biopharmaceuticals' YKP3089 receives Korea Drug Development Fund

South Korean pharmaceutical company SK Biopharmaceuticals announced that the lead drug, YKP3089, from its drug development program for the treatment of refractory epilepsy, has been awarded funding from the Korea Drug Development Fund to support clinical development for the next three years.

3 Mar 2012

Positive results from AltheRx Solabegron Phase II study on overactive bladder

AltheRx Pharmaceuticals, a privately-held clinical development company, presented positive results from its Phase II study of Solabegron in overactive bladder (OAB) at the European Association of Urology Congress in Paris.

1 Mar 2012

Gluten-free diet more of a fad than absolute necessity for many

Many people claim that gluten sensitivity is on the rise and consequently gluten-free products are more popular than ever. A study explores whether shunning gluten is really necessary and finds that in most cases it is not.

22 Feb 2012

Pharmos reports net loss of $0.4 million for fourth quarter 2011

Pharmos Corporation reported financial results for the fourth quarter and twelve-month period ended December 31, 2011. These results are included in the Company's Yearly Report on Form 10-K which has been filed with the SEC.

17 Feb 2012

Ironwood prices public offering of 5,250,000 shares of common stock

Ironwood Pharmaceuticals, Inc. announced today the pricing of an underwritten public offering of 5,250,000 shares of its Class A common stock at a price of $15.09 per share to the public. All of the shares are being offered by Ironwood.

9 Feb 2012

Study implicates 'arms race' between genes and germs

Biologists have found new evidence of why mice, people and other vertebrate animals carry thousands of varieties of genes to make immune-system proteins named MHCs--even though some of those genes make vertebrate animals susceptible to infections and to autoimmune diseases.

9 Feb 2012

Clear link between marijuana use in young males and cyclic vomiting syndrome

Researchers have found clear associations between marijuana use in young males and cyclic vomiting syndrome (CVS), where patients experience episodes of vomiting separated by symptom free intervals.

9 Jan 2012

Stimflora launches new dietary health product

An exciting new dietary health product has been launched which promotes healthy digestion while strengthening the immune system.

7 Jan 2012

Bionomics, Ironwood partner to develop and commercialize novel anti-anxiety compound

Ironwood Pharmaceuticals, Inc. and Bionomics Limited today announced that they entered into a collaboration, research, and licensing agreement that will enable Ironwood to develop and commercialize Bionomics' investigational anti-anxiety compound BNC210 and other related compounds.

5 Jan 2012

Lexicon completes rights offering

Lexicon Pharmaceuticals, Inc. announced today that it has completed its previously announced rights offering pursuant to an effective shelf registration statement.

23 Dec 2011

Salix submits Crofelemer NDA to FDA for treatment of HIV-associated diarrhea

Salix Pharmaceuticals, Ltd. today announced that the Company has submitted to the U.S. Food and Drug Administration (FDA) a New Drug Application (NDA) for Crofelemer for the proposed treatment of HIV-associated diarrhea.

14 Dec 2011

Recommendations to address challenges associated with chronic inflammatory diseases

A dramatic increase in the incidence of chronic inflammatory diseases such as asthma, allergy, and irritable bowel syndrome, has led to concern about how modern lifestyles may trigger physiological defense mechanisms.

8 Dec 2011

First study to investigate risk factors for CCSVI in patients without neurological disease

The first study to investigate risk factors for the vascular condition called CCSVI (chronic cerebrospinal venous insufficiency) in volunteers without neurological disease has identified what the researchers call a remarkable similarity between this condition and possible or confirmed risk factors for multiple sclerosis.

1 Dec 2011

Psychological problems can influence patient's viewpoint of IBS symptom severity

A patient's viewpoint of the severity of irritable bowel syndrome (IBS) symptoms can be influenced not only by physical symptoms of IBS but broader psychological problems, according to a new study in Clinical Gastroenterology and Hepatology, the official journal of the American Gastroenterological Association.

22 Nov 2011

Certain IBD patients at increased risk of skin cancer

Certain patients with inflammatory bowel disease (IBD) may have an increased risk of skin cancer, which is intensified by the use of immunosuppressant medications , according to two new studies in Gastroenterology, the official journal of the American Gastroenterological Association. Immunosuppressants are commonly used in the treatment of IBD.

21 Nov 2011

VSL#3 classified as refrigerated medical food for three GI conditions

As clinical studies continue to validate the use of probiotics to help promote general gastrointestinal health, a growing U.S. market for probiotics indicates that the U.S. healthcare community and consumers alike are recognizing the value of these beneficial microorganisms. However, because most probiotics are classified as dietary supplements, directing patients to the best probiotic for their individual needs can be challenging.

18 Nov 2011

Salix third quarter total product revenue increases 81% to $146.2 million

Salix Pharmaceuticals, Ltd. today announced financial and operating results for the third quarter ended September 30, 2011 and other business updates.

9 Nov 2011